When to Begin Developing the Companion Diagnostic? With Gulzar Sandhu, Agilent Technologies
When should a pharma company begin developing the diagnostic that will identify which patients benefit from a new drug? Early enough to avoid costly delays, but not so early that the company limits the possibilities for the drug. Gulzar Sandhu, Head of Business Development for Biopharma Assay Development at Agilent Technologies, joins us to explore this delicate balance. Companion diagnostics can dramatically improve clinical trial outcomes by identifying patients most likely to respond to a therapy. But developing these tests requires significant investment. Still, to delay can be costly and endanger the entire drug program. ...